All In Biotech

Drug Trial Radar · NCT04259138

Determination of the Optimal Treatment Target in Ulcerative Colitis

VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 672 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

672

Actual

Start

Feb 18, 2020

Primary completion

Apr 13, 2026

Study completion Apr 13, 2026

Sponsor

Lead sponsor
Alimentiv Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Takeda Development Center Americas, Inc.
First posted
Feb 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Disease activity and response to therapy in ulcerative colitis (UC) can be assessed by a range of endpoints including symptoms, endoscopic mucosal activity, histological disease activity, and biomarkers. This study aims to determine the optimal treatment target, which is a research priority for the management of UC both to inform clinical practice and to help inform regulatory endpoints and targets for drug development. Participants with active UC will be randomized in a 5:4:1 (initially 2:3:5) ratio to 1 of 3 groups, each with a different treatment target. Treatment targets will be defined as: * Group 1: corticosteroid-free symptomatic remission * Group 2: corticosteroid-free endoscopic + symptomatic remission * Group 3: corticosteroid-free histological + endoscopic + symptomatic remission An interim analysis was performed to assess the proportion of subjects that reached their assigned treatment target after 50 subjects in each group had reached the first 32-week assessment. The interim analysis and projections made based on target achievement rates for all subjects included in the interim analysis resulted in a recommendation to adjust the randomization ratio from 2:3:5 to 5:4:1 for Groups 1, 2 and 3 respectively as of May 5th, 2023. This change was necessary in order to complete the study with approximately 100 subjects achieving treatment target within each group.

Conditions

  • Colitis, Ulcerative

Interventions

  • Treatment Algorithm ABiological

    Participants who are not on UC treatment at screening (or who have only used topical therapy) will require standard first-line therapy. Either oral 5-ASA and/or immunosuppressive (azathioprine, 6-mercaptopurine, or methotrexate), with optional oral corticosteroid up to a maximum of 30 mg or prednisone or equivalent, will be initiated.

  • Treatment Algorithm BBiological

    Participants who are taking oral 5-ASA, immunosuppressive (azathioprine, 6-mercaptopurine, methotrexate), and/or oral corticosteroid at screening will follow the treatment algorithm. Participants will change to intravenous vedolizumab therapy. Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.

  • Treatment Algorithm CBiological

    Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm. Participants will change to intravenous vedolizumab therapy. Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in Time to UC-related Complication Between Treatment Target Groups 1 and 3Time frame: From date of treatment target achievement until date of first UC-related complication until end of study (Week 96), whichever came first

Locations

58 sites in 10 countries. Site status is shown where the registry gives one.

  • St. Joseph Mercy Hospital/Huron Gastroenterology Associates

    Ypsilanti, Michigan

  • Icahn School of Medicine at Mt Sinai Hospital

    New York, New York

  • New York-Presbyterian/Weill Cornell Medical Center

    New York, New York

  • Digestive Health Partners - Asheville Gastroenterology Associate

    Asheville, North Carolina

  • Atrium Health (Carolinas HealthCare)

    Charlotte, North Carolina

  • Gomel Regional Clinical Hospital

    Homyel, Homiel, Belarus

  • Vitebsk Regional Clinical Hospital

    Vitebsk, Vitebsk Oblast, Belarus

  • Imelda Ziekenhuis Bonheiden

    Bonheiden, Antwerp, Belgium

  • University Hospital Ghent

    Ghent, East Flanders, Belgium

  • UZ Leuven - University Hospital Gasthuisberg

    Leuven, Flemish Brabant, Belgium

  • University of Calgary

    Calgary, Alberta, Canada

  • GIRI (GI Research Institute)

    Vancouver, British Columbia, Canada

  • Barrie GI Associates Inc.

    Barrie, Ontario, Canada

  • McMaster University Medical Centre

    Hamilton, Ontario, Canada

  • London Health Sciences Centre - University Campus

    London, Ontario, Canada

  • LHSC - Victoria Hospital

    London, Ontario, Canada

  • ABP Research Services Corp.

    Oakville, Ontario, Canada

  • Taunton Surgical Centre

    Oshawa, Ontario, Canada

  • Toronto Immune and Digestive Health Institute (TIDHI)

    Toronto, Ontario, Canada

  • McGill University Health Centre (MUHC) Montreal General Hospital

    Montreal, Quebec, Canada

  • CH Saint Etienne Hopital Nord

    Saint-Priest-en-Jarez, Auvergne-Rhône-Alpes, France

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, Bourgogne-Franche-Comté, France

  • CHRU De Nancy - Hopital de Brabois

    Vandœuvre-lès-Nancy, Grand Est, France

  • CHRU de Lille - Hopital Claude Huriez

    Lille, Hauts-de-France, France

  • CHU de Bordeaux - Hopital Haut Leveque - Groupe Hospitalier Sud

    Pessac, New Aquitaine, France

  • CHRU Montpellier - Hopital Saint Eloi

    Montpellier, Occitanie, France

  • Azienda Ospedaliera - Polyclinico Sant'Orsola-Malpighi

    Bologna, Emilia-Romagna, Italy

  • Ospedale San Raffaele S.r.I.

    Milan, Milan, Italy

  • Istituto Clinico Humanitas

    Rozzano, Milan, Italy

  • Azienda Ospedaliera di Padova

    Padova, Padua, Italy

  • Policlinico Universitario Agostino Gemelli

    Roma, Rome, Italy

  • Radboud University Nijmegen Medical Centre

    Nijmegen, Gelderland, Netherlands

  • Catharina Hospital

    Eindhoven, North Brabant, Netherlands

  • ETZ Hospital Tilburg

    Tilburg, North Brabant, Netherlands

  • Amsterdam UMC - Academisch Medisch Centrum

    Amsterdam, North Holland, Netherlands

  • Szpital Miejski Sw. Jana Pawla II w Elblagu

    Elblag, Poland

  • Oddział Gastroenterologiczny SP ZOZ w Łęcznej

    Łęczna, Poland

  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszcz

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • GASTROMED - Kopon, Zmudzinski I Wspolnicy Sp.j.

    Torun, Kuyavian-Pomeranian Voivodeship, Poland

  • Gabinet Endoskopii Przewodu Pokarmowego

    Krakow, Lesser Poland Voivodeship, Poland

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.